Jie Liu

Title: Jie Liu: Innovator in Clinical Synthesis

Introduction

Jie Liu is a prominent inventor based in Alhambra, CA (US). He has made significant contributions to the field of clinical synthesis, particularly in the development of methods for producing essential compounds for medical use. With a total of 3 patents, Liu's work is paving the way for advancements in clinical settings.

Latest Patents

One of Jie Liu's latest patents is focused on the "Methods for multi-dose synthesis of [F-18]FDDNP for clinical settings." This innovative method involves the manufacturing of 2-(1-{6-[(2-[F-18]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)-malononitrile ([F-18]FDDNP). The process utilizes a semi-automated module to perform various tasks such as fluorination, pre-purification, separation, product extraction, and formulation. The method is designed to produce [F-18]FDDNP with high yields, making it ready for human administration under existing FDA regulations. Notably, it eliminates the need for hazardous organic solvents like dichloromethane (DCM), methanol (MeOH), and tetrahydrofuran (THF). Additionally, this synthesis method enhances the speed of production, allowing for a final product to be generated within approximately 90 to 100 minutes. It is also easily adaptable to FDA registered and approved automated synthesis systems.

Career Highlights

Jie Liu is affiliated with the University of California, where he continues to contribute to research and innovation in the field of clinical synthesis. His work is characterized by a commitment to improving the efficiency and safety of medical compound production.

Collaborations

Liu has collaborated with notable colleagues, including Nagichettiar Satyamurthy and Jorge R Barrio. These partnerships have further enriched his research and development efforts.

Conclusion

Jie Liu's innovative methods for synthesizing [F-18]FDDNP represent a significant advancement in clinical settings. His contributions are vital for the future of medical synthesis and patient care.